Navigation Links
Cylene Selected to Present CK2 Inhibitor Multiple Myeloma Data at American Society of Hematology Meeting
Date:12/6/2010

4;BSignaling and Induces Apoptosis in Multiple Myeloma Cells

Session: Myeloma – Pathophysiology and Preclinical Studies, excluding Therapy: Multiple Myeloma – Molecular Target-Based Therapy

Location: Orange County Convention Center, 314

About CK2 and CX-4945

Protein kinase CK2 has emerged as a validated drug target for cancer therapy due to its dysregulation andoverexpression in tumors and its regulatory roles in cell cycle control, DNA damage repair, and in the PI3K/Akt, JAK/STAT, IL-6 and NF-κB signaling cascades.  These pathways have specific relevance in multiple myeloma progression and high levels of CK2 overexpression characterize the disease.  CX-4945 is a potent and highly selective, small molecule inhibitor of CK2 and is currently under evaluation as an orally administered single agent in a Phase I clinical trial in patients with solid tumors (including breast, prostate, pancreatic cancers and inflammatory breast cancer) and a separate Phase I trial in patients with multiple myeloma has recently been initiated.  During the solid tumor trial, CX-4945 has established favorable pharmacokinetic, pharmacodynamic and safety profiles.  Measurement of mechanism and tumor-related biomarkers in patients reveal that CX-4945 hits the CK2 target and down-modulates the PI3K/Akt pathway.  The pharmacokinetic and biomarker data demonstrate that CX-4945 is achieving pharmacologically active levels in plasma and in tumor cells and elicits a clear pharmacodynamic response in humans.  Together, the findings establish CX-4945 as a promising therapeutic agent for targeting multiple cancers.

About Cylene Pharmaceuticals

Cylene Pharmaceuticals, Inc. is a San Diego-based, private biotechnology company, discovering and developing targeted small molecule drugs to treat life-threatening cancers.  Cylene's drug discovery platform, STAND (Selective
'/>"/>

SOURCE Cylene Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cylene to Present Advances with Industrys Only Clinical CK2 Inhibitor, CX-4945, at EORTC-NCI-AACR
2. Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
3. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
4. GENFIT Selected by Windhover for the 2011 Top Biopharma Projects To Watch
5. PolyOne GLS Selected as Healthcare Industry Marketing Specialist for Santoprene™ TPV Medical Grades
6. Sinovac Selected by Beijing CDC to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
7. CSA Medical Selected to Present at AdvaMed 2010: The MedTech Conference
8. The Colorado Institute for Drug, Device and Diagnostic Development Announces Companies Selected From Its First Solicitation: Sophono, Inc., Receiving $600K; and PeptiVir, Inc., $300K
9. Neuronetics Selected by World Economic Forum as 2011 Technology Pioneer
10. Greenway Selected by Health Information Exchanges and Regional Physician Groups
11. Award-Winning Thermal Angel Selected as Winner for Outstanding Military Product of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Kalifornien, 28. August 2014 /PRNewswire/ ... den Start der Patientenrekrutierung für eine ... Forschungsausnahmegenehmigung) zur Beurteilung der Sicherheit und ... von Aneurysmen („WEB") bekanntgegeben. Adam Arthur, MD, ... Department of Neurosurgery/Semmes-Murphey Clinic, und Hauptprüfarzt ...
(Date:8/28/2014)... N.Y. , Aug. 28, 2014 ... have entered a partnership to advance an experimental ... myeloma (SMM), an asymptomatic stage of myeloma. ... Program® (TAP), through which LLS forges collaborations with ... faster. OncoPep is developing a ...
(Date:8/28/2014)... Aug. 28, 2014  STAAR Surgical Company (NASDAQ: ... lenses and delivery systems for the eye, today announced that ... at the New York Palace Hotel on Wednesday, September 3 ... Caldwell , President and CEO will offer a general overview ... developments and be joined by Steve Brown , CFO, ...
Breaking Medicine Technology:Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3The Leukemia & Lymphoma Society Provides Equity Financing to OncoPep to Support Clinical Trial for Myeloma Vaccine 2STAAR Surgical To Present At The Baird 2014 Health Care Conference 2
... Pharma Inc. (Tokyo:4503, "Astellas") announced today that it is ... which will further reinforce the company,s commitment to corporate social ... "We are committed to adopting the Global Compact and ... day-to-day operations of our company and through Astellas, annual ...
... CITY, Nov. 10, 2011 Dynatronics Corporation (NASDAQ: ... ended September 30, 2011 during the morning of Monday, November ... call for investors later that day at 1:30 p.m. ET ... interested in participating should call (800) 926-5230 and use access ...
Cached Medicine Technology:Astellas Signs United Nations Global Compact 2Astellas Signs United Nations Global Compact 3
(Date:8/28/2014)... 70 and over who identify themselves as ,old, feel ... perceive they have lower value than younger age groups. ... Kent, titled ,Being old and ill, across different countries: ... used data from the European Social Survey. Respondents, who ... self-rate their health., The researchers found that those living ...
(Date:8/28/2014)... out how to safely increase the radiotherapy dose given ... control and survival. , Standard treatment for locally advanced ... and chemotherapy. Traditionally this is planned in a one-size-fits-all ... enough to stop tumour growth. , The potential to ... between patients and depends on the size and location ...
(Date:8/28/2014)... Vaccine market - the once low-profit ... other healthcare industry sectors and sub-circles in the U.S. ... with respect to evolving and spreading infectious diseases. This ... improved understanding for a well-balanced life and improved immune ... led to new opportunities for manufacturing novel preventive and ...
(Date:8/28/2014)... Minneapolis, Minn. (PRWEB) August 28, 2014 ... in North America, today announced the launch of its ... business with AmeriPride even easier and more convenient for ... account information online and better communicate with the company. ... ability to:, Access, download and ...
(Date:8/28/2014)... 2014 After more than two years ... is excited to announce the opening of Houston’s Mirror ... any city, Mirror Mirror Beauty Boutique offers premium aesthetic ... the corner of Richmond and Drexel near Highland Village, ... and cutting-edge technology in a private, easy to access ...
Breaking Medicine News(10 mins):Health News:Research demonstrates potential method to better control lung cancer using radiotherapy 2Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 2Health News:U.S. Vaccine Market: Opportunities and Threats by Transparency Market Research 3Health News:AmeriPride Services Launches New Customer Portal 2Health News:AmeriPride Services Launches New Customer Portal 3Health News:Mirror Mirror Beauty Boutique to Welcome Its First Patients 2
... for the first time that human embryonic stem cells ... mature T-cells//, raising hopes for a gene therapy to ... and the Institute for Stem Cell Biology and Medicine ... embryonic stem cells into blood-forming stem cells that in ...
... recent survey it was found that international nurses would need to ... NHS//. ,The step was mainly taken to give jobs ... nurses come to Britain from outside the European Union every year. ... the Philippines and Australia. The rule applies to nurses in bands ...
... 45 seconds, another American has a stroke, caused either by a ... minutes//, one of them will die. ,That's the bad news. ... to find and fix the problems that cause many strokes — ... ever having to open up the skull. ,New technologies, ...
... Dr. Bing-Huei Chen and colleagues it was found that ... form during cooking. ,The research was conduced ... Products (COPs) is produced when cholesterol-rich foods are processed ... the body cells leading to heart disease or cancer. ...
... California Supreme Court said that partners must inform their spouse about ... ,This came down as the court ruling in San Francisco when ... court. The wife accused the ex-husband of transmitting AIDS to her. ... decided that the spouse or partner of a person who has ...
... from the Korea Research Institute of Bioscience and Biotechnology//. ... found a human gene that aids in the growth and spread ... about the discovery and said that it would help in the ... was mainly conducted on mice and the research team found that ...
Cached Medicine News:Health News:T-cells Developed from Human Embryonic Stem Cells 2Health News:Brain Surgery Without the Surgery? 2Health News:Brain Surgery Without the Surgery? 3Health News:Brain Surgery Without the Surgery? 4Health News:Brain Surgery Without the Surgery? 5Health News:Brain Surgery Without the Surgery? 6
... The design of the Hi-Top ... to be held back in ... shoe counter. The front is ... and compression on the toes. ...
... semi-rigid post op shoe is ideal for ... breathable upper will keep your patient both ... closure provides even tension and compression. The ... support for your patient. The black TPR ...
Comfortably positions the affected foot at 90 to provide continuous and effective stretching of the plantar fascia and Achilles Tendon...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
Medicine Products: